Home Featured Page 199

Featured

Latest

Dylan Beynon – Mindbloom – At Home Ketamine

Beckley’s 5-MeO-DMT Shows Rapid, Durable Antidepressant Effects in Phase 2b Study

Beckley Execs Talk Phase 2b Data, Competition, and Phase 3 Plans

Beckley and atai Leadership Unpack Phase 2b Data, Take Aim at GH’s Dosing Model

Beyond the Endpoint: Industry Voices Reflect on Compass’ Phase 3 Readout

Filament Health Announces FDA Authorization of Clinical Trial with First-Ever Direct...

Field Trip Health Ltd. Schedules Second Fiscal Quarter 2022 Financial Results...

Tryp Therapeutics Submits IND Application for Phase 2a Clinical Trial in...

PT269 – Adam Strauss – Comedy, OCD, and The Mushroom Cure

Psychedelic Research Bulletin: October 2021

The Compounds in Psychedelic Cacti

atai Life Sciences Announces Supportive Interim Data from First 8-Patient Cohort...

Red Light Holland Appoints New Chief Financial Officer

PharmaDrug Expands Product Offering to Prepare for Potential Adult Use Market...

Algernon Pharmaceuticals Establishes 6 hours as Optimum Treatment Period for DMT...

1...198199200...291 Page 199 of 291

EDITOR PICKS

Dylan Beynon – Mindbloom – At Home Ketamine

Beckley’s 5-MeO-DMT Shows Rapid, Durable Antidepressant Effects in Phase 2b Study

Beckley Execs Talk Phase 2b Data, Competition, and Phase 3 Plans

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

ABOUT US

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

Dylan Beynon – Mindbloom – At Home Ketamine

Beckley’s 5-MeO-DMT Shows Rapid, Durable Antidepressant Effects in Phase 2b Study

Beckley Execs Talk Phase 2b Data, Competition, and Phase 3 Plans

Beckley and atai Leadership Unpack Phase 2b Data, Take Aim at GH’s Dosing Model

Beyond the Endpoint: Industry Voices Reflect on Compass’ Phase 3 Readout

Filament Health Announces FDA Authorization of Clinical Trial with First-Ever Direct...

Field Trip Health Ltd. Schedules Second Fiscal Quarter 2022 Financial Results...

Tryp Therapeutics Submits IND Application for Phase 2a Clinical Trial in...

PT269 – Adam Strauss – Comedy, OCD, and The Mushroom Cure

Psychedelic Research Bulletin: October 2021

The Compounds in Psychedelic Cacti

atai Life Sciences Announces Supportive Interim Data from First 8-Patient Cohort...

Red Light Holland Appoints New Chief Financial Officer

PharmaDrug Expands Product Offering to Prepare for Potential Adult Use Market...

Algernon Pharmaceuticals Establishes 6 hours as Optimum Treatment Period for DMT...

EDITOR PICKS

Dylan Beynon – Mindbloom – At Home Ketamine

Beckley’s 5-MeO-DMT Shows Rapid, Durable Antidepressant Effects in Phase 2b Study

Beckley Execs Talk Phase 2b Data, Competition, and Phase 3 Plans

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY